Cogent Biosciences (NASDAQ:COGT) Given “Outperform” Rating at Wedbush

Posted by on May 29th, 2026

Cogent Biosciences (NASDAQ:COGT – Get Free Report)‘s stock had its “outperform” rating reissued by investment analysts at Wedbush in a note issued to investors on Friday,Benzinga reports. They presently have a $55.00 price objective on the technology company’s stock. Wedbush’s price target would suggest a potential upside of 56.44% from the company’s current price.

Other equities research analysts have also recently issued research reports about the company. Jefferies Financial Group started coverage on Cogent Biosciences in a report on Monday, March 16th. They set a “buy” rating and a $55.00 price objective on the stock. HC Wainwright upped their target price on Cogent Biosciences to $55.00 and gave the company a “buy” rating in a research note on Wednesday, May 6th. Piper Sandler increased their target price on Cogent Biosciences from $39.00 to $52.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 18th. Wall Street Zen lowered Cogent Biosciences from a “hold” rating to a “sell” rating in a research note on Saturday, January 31st. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Cogent Biosciences in a report on Friday, April 10th. Two equities research analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $43.73.

Check Out Our Latest Stock Analysis on COGT

Cogent Biosciences Trading Down 0.6%

Shares of NASDAQ COGT traded down $0.22 during midday trading on Friday, reaching $35.16. 108,191 shares of the stock were exchanged, compared to its average volume of 2,033,239. The stock has a 50 day moving average price of $35.27 and a 200-day moving average price of $36.72. The company has a current ratio of 15.14, a quick ratio of 15.14 and a debt-to-equity ratio of 0.41. The company has a market capitalization of $6.01 billion, a P/E ratio of -16.23 and a beta of 0.37. Cogent Biosciences has a 52-week low of $5.03 and a 52-week high of $43.73.

Cogent Biosciences (NASDAQ:COGT – Get Free Report) last announced its earnings results on Tuesday, May 5th. The technology company reported ($0.53) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.53). Equities research analysts expect that Cogent Biosciences will post -2.23 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in COGT. Vanguard Group Inc. grew its position in Cogent Biosciences by 48.4% during the fourth quarter. Vanguard Group Inc. now owns 11,514,326 shares of the technology company’s stock valued at $408,989,000 after acquiring an additional 3,756,664 shares during the period. Deerfield Management Company L.P. raised its holdings in shares of Cogent Biosciences by 242.9% in the 3rd quarter. Deerfield Management Company L.P. now owns 9,053,118 shares of the technology company’s stock worth $130,003,000 after purchasing an additional 6,412,903 shares during the period. Fairmount Funds Management LLC lifted its stake in shares of Cogent Biosciences by 44.6% in the 3rd quarter. Fairmount Funds Management LLC now owns 9,003,418 shares of the technology company’s stock valued at $129,289,000 after purchasing an additional 2,777,777 shares in the last quarter. RTW Investments LP lifted its stake in shares of Cogent Biosciences by 119.0% in the 4th quarter. RTW Investments LP now owns 7,592,241 shares of the technology company’s stock valued at $269,676,000 after purchasing an additional 4,124,755 shares in the last quarter. Finally, Commodore Capital LP grew its holdings in shares of Cogent Biosciences by 213.7% during the 3rd quarter. Commodore Capital LP now owns 7,250,000 shares of the technology company’s stock worth $104,110,000 after purchasing an additional 4,938,836 shares during the period.

Cogent Biosciences Company Profile

(Get Free Report)

Cogent Biosciences is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that modulate the tumor microenvironment. The company’s research centers on targeting colony-stimulating factor 1 receptor (CSF1R), a key regulator of tumor-associated macrophages that can promote tumor growth and immune evasion. By selectively inhibiting CSF1R, Cogent Biosciences aims to restore immune surveillance and enhance the efficacy of existing cancer treatments.

The company’s lead asset is an orally bioavailable CSF1R inhibitor that has advanced into early-stage clinical trials for various solid tumors.

Read More

Analyst Recommendations for Cogent Biosciences (NASDAQ:COGT)

Receive News & Ratings for Cogent Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cogent Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.